Desferrioxamine in warm reperfusion media decreases liver injury aggravated by cold storage

Peter G Arthur, Xian-Wa Niu, Wen-Hua Huang, Bastiaan DeBoer, Ching Tat Lai, Enrico Rossi, John Joseph, Gary P Jeffrey

AIM: To evaluate whether desferrioxamine decreases ischemia and perfusion injury aggravated by cold storage (CS) in a rat liver perfusion model.

METHODS: Isolated rat livers were kept in CS in University of Wisconsin Solution for 20 h at 4 °C, then exposed to 25 min of warm ischemia (WI) at 37 °C followed by 2 h of warm perfusion (WP) at 37 °C with oxygenated (95% oxygen and 5% carbon dioxide) Krebs-Henseleit buffer. Desferrioxamine (DFO), an iron chelator, was added at different stages of storage, ischemia and perfusion: in CS only, in WI only, in WP only, in WI and perfusion, or in all stages. Effluent samples were collected after CS and after WI. Perfusate samples and bile were collected every 30 min (0, 0.5, 1, 1.5 and 2 h) during liver perfusion. Cellular injury was assessed by the determination of lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) in the effluent and perfusate samples. Total iron was analysed in the perfusate samples. After WP, the liver was collected for the determination of liver swelling (wet to dry ratio) and liver morphological examination (hematoxylin and eosin staining).

RESULTS: Increased CS time caused increased liver dysfunction during WP. After 2 h of WP, liver injury was indicated by increased release of AST (0.5 h CS: 9.4 ± 2.2 U/g liver vs 20 h CS: 45.9 ± 10.8 U/g liver, P < 0.05) and LDH (0.5 h CS: 59 ± 14 U/g liver vs 20 h CS: 297 ± 71 U/g liver, P < 0.05). There was an associated increase in iron release into the perfusate (0.5 h CS: 0.11 ± 0.03 µmol/g liver vs 20 h CS: 0.58 ± 0.10 µmol/g liver, P < 0.05) and reduction in bile flow (0.5 h CS: 194 ± 12 µL/g liver vs 20 h CS: 71 ± 8 µL/g liver, P < 0.05). When DFO was added following 20 h of CS, release of iron into the perfusate was decreased (DFO absent 0.31 ± 0.06 µmol/g liver vs DFO present 0.31 ± 0.06 µmol/g liver, P < 0.05), and liver function substantially improved with decreased release of AST (DFO absent 45.9 ± 10.8 U/g liver vs DFO present 8.1 ± 0.9 U/g liver, P < 0.05) and LDH (DFO absent 297 ± 71 U/g liver vs DFO present 56 ± 7 U/g liver, P < 0.05), and increased bile flow (DFO absent 71 ± 8 µL/g liver vs DFO present 237 ± 36 µL/g liver, P < 0.05). DFO was also shown to improve liver morphology after WP. Cellular injury (the release of LDH and AST) was significantly reduced with the addition of DFO.
DFO in CS medium but to a lesser extent compared to the addition of DFO in WP or WI and perfusion. There was no effect on liver swelling or bile flow when DFO was only added to the CS medium.

CONCLUSION: DFO added during WI and perfusion decreased liver perfusion injury aggravated by extended CS.

© 2013 Baishideng. All rights reserved.

Key words: Iron chelation; Ischemia and perfusion injury; Liver; Organ preservation; Rat

INTRODUCTION

Hypothermia is used extensively to preserve many types of donor organs for transplantation and protects organs, in part, by reduced requirements for metabolic energy[1]. Donor livers are flushed and then stored at 4°C in specialized storage solutions (e.g., University Wisconsin solution). However, preservation injury can cause primary graft dysfunction and increased morbidity and mortality in liver transplant recipients[2]. When cold storage (CS) time is extended beyond 10 h, there is a significant increase in primary graft dysfunction and long term biliary complications following liver transplantation[3,6]

The mechanisms responsible for donor liver dysfunction after preservation are not fully understood but one important potential contributor to liver damage is redox active iron. Redox active iron has been identified as a contributor to isolated hepatectomy death and liver damage during hypothermia[7-10]. Redox active iron can react with hydrogen peroxide and initiate radical reactions which damage cellular macromolecules, such as DNA, proteins and membrane lipids. Chelation of iron by specialised macromolecules like DFO could abrogate the activity of the iron in lethal free iron. Iron chelators such as DFO has been shown to be protective in in vivo and in vitro studies[7,10,11]. When cells or organs are cooled there is an increase in redox active iron and this increase has been linked to cell death during hypothermia[7,9,14].

One approach to abrogating the activity of redox active iron is to chelate free iron with iron chelators such as desferrioxamine (DFO)[7,9,13]. When DFO was added to CS media there was reduced hepatocyte death and endothelial cell death during CS, and liver damage on re-perfusion[7,14,16]. However, it is unlikely that DFO is taken up intracellularly by liver cells during storage at 4°C. In contrast, redox active iron has the potential to predispose the donor liver to injury during implantation (warm ischemia (WI)) and subsequent re-perfusion[14]. DFO enters tissue by endocytosis at 37°C and therefore the presence of DFO during WI and re-perfusion may offer additional protection from CS injury. To test this hypothesis, isolated rat livers were perfused after CS, with DFO added to the preservation media during CS and WP. This strategy significantly protected livers from CS damage.

MATERIALS AND METHODS

Materials

Krebs-Henseleit buffer (KHB), DFO and reduced glutathione were purchased from SIGMA and Aldrich, Sydney, Australia. Hartmann’s solution was obtained from Baxter Health Care Pty Ltd, Old Toongabbie, Australia, University of Wisconsin solution (UWS) from Bristol-Myers Squibb Company, New York, United States, gentamicin from Pfizer, West Ryde, Australia and Actrapid human insulin from Novo Nordisk Pharmaceuticals Pty Ltd, Baulkham Hills, Australia. Dexamethasone sodium phosphate was from AstraZeneca, Rowville, Australia.

Liver isolation, CS and WI

The use of animals was approved by the Animal Ethics Committee of the University of Western Australia. All animals received food and water before graft retrieval. Adult male rats (strain PVG, average weight 272 ± 5 g, n = 35) were anesthetized with halothane. The gastroduodenal, splenic vein, right renal artery, right and left adrenal veins were ligated and the bile duct was cannulated. The liver was flushed with 20 mL of cold Hartmann’s solution (control) or UWS with supplements (reduced glutathione, dexamethasone, insulin and gentamicin, pH 7.35-7.4 on ice) and heparin (5 U/mL) into the aorta. The liver was excised and placed in UWS with supplements for 20 h at 2-4°C. After CS the suprahepatic vena cava (outlet) and portal vein (inlet) were cannulated, and the liver was connected to a rat liver perfusion system while it was in the CS medium. In the control group, after the liver was excised, the liver was connected to a rat liver perfusion system while it was in cold saline for up to 0.5 h (CS0.5 h). The liver was then transferred to the perfusion chamber (37°C) and flushed with 20 mL of Hartmann’s solution and heparin (5 U/mL). The first 6.5 mL of effluent and the CS medium were collected. To simulate WI during liver implantation, the liver was covered with damp gauze and left at 37°C chamber for 25 min.

Liver WP

After WI, the liver was perfused using a water-jacketed perfusion system (Radnoti Glass Technology, Inc., Monrovia, United States) with oxygenated (95% oxygen and 5% carbon dioxide) KHB at 20 mL/min at 37°C and the first 6.5 mL of perfusate was collected. After 7.5 min of perfusion, the perfusate was re-circulated and filtered through a pre-filter and filter (0.8 µm/0.2 µm, 32 mm OD, Pall Life Sciences, Australia) and the liver was then perfused for 2 h. During liver perfusion, perfusate (1.5 mL) and bile were collected at 0, 0.5, 1, 1.5 and 2 h and
kept on ice. Perfusates were centrifuged at 10 000 g for 10 min at 4°C and the supernatant was analysed for lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and total iron.

After 2 h of perfusion, the liver was pat-dried and weighed. Tissue (approximately 0.5 g) was dried at 80°C for 72 h for the calculation of wet to dry ratio and a portion of tissue was snap frozen in liquid nitrogen for subsequent analysis. The remaining liver was fixed in 10% formaldehyde for histopathological examination.

**Assays**

Perfusate LDH levels were measured by the method of Passonneau [19]. AST enzyme activity was measured by automated biochemical analyser (Hitachi 917, Roche Diagnostics). Total iron levels were measured by Inductively Coupled Plasma-Mass Spectrometry (Varian 820, California, United States) with aqueous standards used for the calibration curve. LDH, AST and total iron were expressed relative to dry liver weight.

**Liver histopathology**

Liver sections were stained with hematoxylin and cosin and then examined independently by a pathologist (B DeBoer) and a hepatologist (GP Jeffrey). A scale for morphological classification of hepatic injury was used as previously described [20]. The 9 point scale was: (1) normal rectangular structure; (2) round hepatocytes with an increase of sinusoidal spaces; (3) vacuolization in zone 3; (4) vacuolization in zone 2; (5) vacuolization in zone 1; (6) vacuolization and nuclear pyknosis in zone 3; (7) vacuolization and nuclear pyknosis in zone 2; (8) vacuolization and nuclear pyknosis in zone 1; and (9) necrosis.

**DFO addition to media**

There were seven experimental groups and each group consisted of 5 rats. DFO (1 mmol/L) was tested in five experimental groups with different combinations of DFO during CS, WI, WP and perfusion (WIP), or CS, WI and perfusion (CS WIP) (Table 1). The required amount of DFO was weighed and added to the media prior to use and the concentration (1 mmol/L) was based on our previous isolated rat hepatocyte study [21].

### Table 1 Details of experimental groups

| Experimental group | Number per group | CS time (h) in UWS | Addition of DFO |
|--------------------|------------------|--------------------|----------------|
| CS0.5 h            | 5                | -                  | -              |
| CS20 h             | 5                | 20                 | -              |
| DFO (CS)           | 5                | 20                 | DFO            |
| DFO (WI)           | 5                | 20                 | DFO            |
| DFO (WP)           | 5                | 20                 | DFO            |
| DFO (WIP)          | 5                | 20                 | DFO            |
| DFO (CS-WIP)       | 5                | 20                 | DFO            |

DFO: Desferrioxamine; CS: Cold storage; UWS: University of Wisconsin solution; WI: Warm ischemia; WP: Warm perfusion; WIP: Warm ischemia and perfusion.

**RESULTS**

**Effect of extended CS**

The degree to which liver damage occurred during CS, WI and WP was measured by the release of LDH and AST. Liver damage was evident immediately after extended CS. The LDH level was 7.9 ± 0.6 U/g liver and the AST level was 1.9 ± 0.1 U/g liver after 20 h of CS compared to 0.7 ± 0.1 U/g liver and 0.1 ± 0.0 U/g liver in the controls (CS0.5 in Figure 1). Increased damage was also evident after WI, with 9 fold higher LDH and 8 fold higher AST release in extended CS, relative to the controls (CS0.5 in Figure 1). The bulk (more than 95%) of LDH and AST release occurred during WP of livers subjected to extended CS (Figure 1). After 2 h of perfusion, LDH levels were 297 ± 71 U/g liver and AST levels were 45.9 ± 10.8 U/g liver in livers subjected to 20 h of CS compared to 59 ± 14 U/g liver and 9.4 ± 2.2 U/g liver respectively in livers of the control group. Twenty hours of CS resulted in a 14% increase in liver swelling and a 63% decrease in bile flow (Figure 1). Taken together, these data indicate that 20 h of CS caused a detrimental effect on liver function during subsequent WI and WP.

**Protective effect of DFO**

DFO was first added to CS medium only. There was no significant improvement in LDH levels or AST levels during WI. However during WP there was a 40% reduction of LDH and AST levels after 2 h of perfusion compared to livers that had not been exposed to DFO during CS (Figure 2). There was no effect on liver swelling or bile flow (Figure 2).

To test if either redox active iron was not completely chelated by DFO during CS, or additional redox active iron release occurred during WI and WP, DFO was added to solutions during all stages of the experiment. This resulted in a significant reduction of AST levels from 6.7 ± 1.3 U/g liver to 3.4 ± 0.5 U/g liver compared with no DFO during WI (P < 0.05). LDH levels were not significantly affected (DFO absent 39.9 ± 7.9 U/g liver vs DFO present 24.4 ± 2.5 U/g liver). In contrast, after 2 h of WP there was a large reduction of AST levels and LDH levels from 45.9 ± 10.8 U/g liver to 8.1 ± 0.9 U/g liver and 297 ± 71 U/g liver to 56 ± 7 U/g liver respectively when compared to no DFO (Figure 2). These levels were similar to the controls (CS0.5 in Figure 1). Consistent DFO effects were observed with improved liver swelling, decreased from 4.01 ± 0.17 to 3.37 ± 0.05 (wet weight to dry weight ratio) and bile flow increased from 71 ± 8
To test the possibility that DFO had its predominant protective effect during WI and/or WP, DFO was added to either WI or WP media alone. DFO had no effect when added during WI alone, however there was a protective effect when it was added to perfusion medium alone (Figure 2). There was a reduction of LDH from 297 ± 71 U/g liver to 72 ± 15 U/g liver and AST from 45.9 ± 10.8 U/g liver to 13.4 ± 2.2 U/g liver compared to livers not treated with DFO (Figure 2). Furthermore, liver swelling was prevented and bile flow was maintained (Figure 2). Of note, the protective effect was comparable to that observed when DFO was present during all three stages of the experiment and this is consistent with the concept that redox active iron continued to be a major cause of liver damage during WI and WP following extended CS.

To further assess the protective effect of DFO, liver morphology was examined following 2 h of WP and assessed using a nine point scale ranging from 1 (normal structure) to 9 (necrosis) (Figure 3). Relative to the controls (CS0.5 h, morphological classification of 3.0 ± 0.1, mean ± SE, n = 4), extended CS resulted in extensive vacuolization and marked pyknosis (morphological classification of 5.5 ± 0.9, mean ± SE, n = 4, P < 0.05). DFO was largely effective in preventing changes to liver morphology (morphological classification of 3.0 ± 0.4, mean ± SE, n = 4, P < 0.05 relative to no DFO).

Iron release during CS and perfusion
The effectiveness of DFO in preventing liver damage indicated redox active iron was likely a major contributor to liver damage. To further investigate this, iron release was measured following WI and during perfusion. Following WI and 20 h of CS there was 0.15 ± 0.02 µmol/L iron/g liver compared with 0.02 ± 0.01 µmol/L iron/g liver in the controls (CS0.5 in Figure 4, P < 0.05). After 2 h of WP, iron release after 20 h of CS was 0.58 ± 0.10 µmol/L iron/g liver which was significantly higher than 0.11 ± 0.03 µmol/L/g liver in the controls (CS0.5 in Figure 4, P < 0.05). Iron concentrations were significantly correlated with LDH release and AST release during WI (Figure 5). During WP, the concentration of iron was also correlated with LDH release and AST release (Figure 5). The significant correlation between iron and the damage markers LDH and AST was consistent with the hypothesis that redox active iron was causing liver damage.

The presence of DFO altered iron concentrations in livers to 237 ± 36 µL/g liver (Figure 2). To further assess the protective effect of DFO, liver morphology was examined following 2 h of WP and assessed using a nine point scale ranging from 1 (normal structure) to 9 (necrosis) (Figure 3). Relative to the controls (CS0.5 h, morphological classification of 3.0 ± 0.1, mean ± SE, n = 4), extended CS resulted in extensive vacuolization and marked pyknosis (morphological classification of 5.5 ± 0.9, mean ± SE, n = 4, P < 0.05). DFO was largely effective in preventing changes to liver morphology (morphological classification of 3.0 ± 0.4, mean ± SE, n = 4, P < 0.05 relative to no DFO).
WP media. When DFO was added during CS, WI and perfusion, iron concentrations were significantly decreased from 0.58 ± 0.10 µmol/g liver (no DFO) to 0.31 ± 0.06 µmol/g liver (with DFO, \( P < 0.05 \)) (Figure 4). There was also a significant relationship between the concentration of iron and liver damage during both WI and WP (Figure 5). However, the slope of the line describing the relationship was significantly lower in the presence of DFO compared to the absence of DFO during WP (Figure 5). Consequently, for the same concentration of iron, there was less damage in the presence of DFO relative to absence of DFO. One explanation for this observation may be that by chelating iron during WI or perfusion, DFO prevented ongoing liver damage caused by redox active iron.

**DISCUSSION**

It is well established that extended CS causes increased liver damage and that the presence of iron chelators in storage media can substantially protect hepatocytes and livers from damage during cold incubation or storage\(^{10,14,23,24}\). In this study, extended CS also aggravated liver damage during the simulated transplantation protocol involving WI (mimicking implantation) and WP. The presence of DFO during CS only partially decreased the subsequent vulnerability of livers to the simulated transplantation protocol. The novel finding of this study was that the presence of DFO during WI and WP could substantially decrease the vulnerability of livers to extended CS.

Liver damage during WP was related to events occurring during CS, such that extended CS sensitised the liver to subsequent WI and perfusion injury. Redox active iron has been identified as a contributor to hepatocyte death\(^{10}\) and liver damage during CS\(^{10,14}\). Data from this study provided evidence that redox active iron was involved in sensitising the liver during extended CS, as the presence of DFO during CS did partially protect against subsequent liver damage. There is evidence that DFO is not able to cross membranes during incubation at 4 °C\(^{14}\), so by what mechanism did DFO partially protect the liver in this present model? Iron is present in UWS solu-
tion as measured in our laboratory (4.43 ± 0.05 µmoL/L, n = 4) and in another study[25], so the protective effect of DFO added during CS could be a result of chelation of extracellular iron. It has also been suggested that DFO is able to reduce intracellular iron by draining cytosolic iron to the extracellular medium[26]. Consistent with this concept, we have previously shown that chelation of extracellular iron protects hepatocytes during cold incubation[7]. Therefore, during extended CS, extracellular iron could have contributed to the sensitization of livers to subsequent WI and perfusion injury.

Intracellular redox active iron could have also contributed to the sensitization of livers to subsequent WI and perfusion injury. Intracellular redox active iron has been shown to increase during cold incubation/storage in isolated hepatocytes[9,11] and whole liver[14]. Additionally, we have linked increased intracellular redox active iron to hepatocyte cell death during extended cold incubation[7]. In previous experiments not involving CS, redox active iron has been implicated in renal ischemia and perfusion injury[12,27] and ischemia and perfusion injury in livers[28]. Therefore, an increase in the concentration of intracellular redox active iron caused by the extended CS would exacerbate an ongoing cycle of redox active iron release during WI and WP. This explanation would account for the added effectiveness of DFO during WI and WP.

The findings of this study have implications for liver transplantation. There has been a focus on protecting livers during CS by developing various cryoprotective media or improving liver function prior to transplant us-

**Figure 3** Histopathological appearance of livers following cold storage, warm ischemia and perfusion and the effect of desferrioxamine. A: The control liver shows some early vacuolization in zone 2 following 0.5 h of cold storage (CS0.5) (magnified insert); B: Following 20 h of cold storage (CS20), the liver shows marked vacuolization and nuclear pyknosis in zones 3 as indicated by arrows (←, magnified insert); C: Following 20 h of CS with desferrioxamine (DFO) in CS, warm ischemia and perfusion media (CS WIP), the liver shows mild vacuolization in zone 3 (magnified insert). Hematoxylin and eosin staining and the original magnification was 100 ×. PT: Portal tract; CV: Central vein.
### Figure 4 Iron release during warm ischemia and perfusion and effect of desferrioxamine on iron release.

**A:** Iron release was measured in media after warm ischemia (WI) and at 1 and 2 h of perfusion from the control livers after 0.5 h of cold storage (CS0.5) and from the livers after 20 h of extended cold storage (CS20). Significantly different from the controls (mean ± SE, \( n = 5 \), \( \text{P} < 0.05 \)).

**B:** Iron release was measured in media after 1 and 2 h of perfusion from livers following 20 h of cold storage (CS). Addition of desferrioxamine (DFO) to CS, WI and perfusion media is indicated by (+). Significantly different from 20 h of CS with no DFO (mean ± SE, \( n = 5 \), \( \text{P} < 0.05 \)).

### Figure 5 Relationship between presence of iron and liver damage.

Following ischemia: **A:** The relationships between lactate dehydrogenase (LDH) and iron in the absence of desferrioxamine (DFO) (circles) and the presence of DFO (crosses) were described by \( y = 327x - 5 \) (\( n = 19 \), \( r^2 = 0.84 \)) and \( y = 162x + 6 \) (\( n = 14 \), \( r^2 = 0.69 \)) respectively; **B:** The relationships between aspartate aminotransferase (AST) and iron in the absence of DFO (circles) and the presence of DFO (crosses) were described by \( y = 52x - 0.9 \) (\( n = 19 \), \( r^2 = 0.81 \)) and \( y = 33x + 1 \) (\( n = 14 \), \( r^2 = 0.44 \)).

During perfusion, samples collected at 0.5 h, 1 h, 1.5 h and 2 h were analysed. **C:** The relationships between LDH and iron in the absence of DFO (circles) and the presence of DFO (crosses) were described by \( y = 487x - 8.1 \) (\( n = 76 \), \( r^2 = 0.88 \)) and \( y = 291x - 24.4 \) (\( n = 56 \), \( r^2 = 0.91 \)) respectively; **D:** The relationships between AST and iron in the absence of DFO (circles) and the presence of DFO (crosses) were described by \( y = 81x - 0.5 \) (\( n = 76 \), \( r^2 = 0.90 \)) and \( y = 62x - 5.6 \) (\( n = 56 \), \( r^2 = 0.80 \)) respectively. All correlation coefficients were significant (\( \text{P} < 0.05 \)), and all slopes for media containing iron were significantly different (\( \text{P} < 0.05 \)) from the equivalent treatment without DFO.
Desferrioxamine reduces liver hypothermia reperfusion injury

Arthur PG et al. Desferrioxamine reduces liver hypothermia reperfusion injury

Background
Cold donor organ preservation techniques were developed to reduce cellular metabolic activity and maintain cellular viability in donor organs. However, livers stored beyond about 12 h are generally considered to be unsuitable for transplantation.

Research frontiers
Extending the time of cold storage (CS) increases the susceptibility of livers to ischemia and reperfusion injury during transplantation. Preventing ischemia and reperfusion injury would permit extended times of CS.

Innovations and breakthroughs
Desferrioxamine (DFO), an iron chelator, is often included in CS media to prevent oxidative stress caused by redox active iron. The novel finding of this study was that including DFO during warm ischemia and warm perfusion could prevent oxidative stress caused by redox active iron. In published studies on the respiratory activity of 0 degrees C. Cryo Letters 2007; 28: 313-328 [PMID: 18075701]

Applications
This study shows that it is possible to extend the time in which livers can be kept in CS. Extended CS times would improve the numbers of livers available for transplant.

Peer review
This is an experimental study of correct methodology. The bibliography is sorted correctly.

REFERENCES
1. Llarrull MS, Pizarro MD, Scandizzi AL, Bottai H, Guibert EE, Rodriguez JV. Cold preservation of isolated hepatocytes in UW solution: experimental studies on the respiratory activity at 0 degrees C. Cryo Letters 2007; 28: 313-328 [PMID: 18075701]
2. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20: 829-838 [PMID: 7927223 DOI: 10.1002/hep.1840200410]
3. Defamie V, Laurens M, Patrono D, Devel L, Brault A, Saint-Jacques P, Meurisse M, Defraigne JO. Intracellular free iron content of rat liver tissue after cold ischemia. Hepatology 2002; 35: 560-567 [PMID: 11870368 DOI: 10.1053/jhep.2003.50065]
4. Cable H, Lloyd JB. Cellular uptake and release of two contrasting iron chelators. J Pharm Pharmacol 1999, 51: 131-134 [PMID: 10217310 DOI: 10.1211/0022357991772231]
5. Emerit J, Baumont C, Trivin F. Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother 2001; 55: 333-339 [PMID: 11476586 DOI: 10.1016/S0753-3322(00)00683-X]
6. Vreugdenhil PK, Rankin MA, Southard JH. Cold storage sensitizes hepatocytes to oxidative stress injury. Transplant Int 1997; 10: 379-385 [PMID: 9287404 DOI: 10.1007/s001470050074]
7. Cable H, Lloyd JB. Cellular uptake and release of two contrasting iron chelators. J Pharm Pharmacol 1999, 51: 131-134 [PMID: 10217310 DOI: 10.1211/0022357991772231]
8. Emerit J, Baumont C, Trivin F. Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother 2001; 55: 333-339 [PMID: 11476586 DOI: 10.1016/S0753-3322(00)00683-X]
9. Lloyd JB, Cable H, Rice-Evans C. Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem Pharmacol 1991; 41: 1361-1363 [PMID: 2018567 DOI: 10.1016/0006-2952(91)90109-4]
10. Passonneau JV, Lowry OH. Chapter 7: A collection of enzyme assays. In: Enzymatic analysis: a practical guide. Totowa, New Jersey: Humana Press, 1993; 281
11. Bessesms M, Doorschodt BM, van Vliet AK, van Gulik TM. Improved rat liver preservation by hypothermic continuous machine perfusion using polysol, a new, enriched preservation solution. Liver Transpl 2005; 11: 539-546 [PMID: 15838888 DOI: 10.1002/lt.20388]
12. The R Core Team. R: A Language and Environment for Statistical Computing [Computer program]. Vienna: R Foundation for Statistical Computing, 2010
13. De Mediburur F, Agricole: Statistical Procedures for Agricultural Research. R package version 1.09-9 [Computer program]. Vienna: R Foundation for Statistical Computing, 2010
14. Bahde R, Palmes D, Gemsa O, Minin E, Stratmann U, de Groot H, Rauen U, Spiegel HU. Attenuated cold stor-
Desferrioxamine reduces liver hypothermia reperfusion injury

Huang H, He Z, Roberts LJ, Salahudeen AK. Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model. *Am J Transplant* 2003; 3: 1531-1537 [PMID: 14629283 DOI: 10.1046/j.1600-6135.2003.00264.x]

Evans PJ, Tredger JM, Dunne JB, Halliwell B. Catalytic metal ions and the loss of reduced glutathione from University of Wisconsin preservation solution. *Transplantation* 1996; 62: 1046-1049 [PMID: 8900298 DOI: 10.1097/00007890-199610270-00002]

Tenopoulou M, Doulias PT, Barbouti A, Brunk U, Galaris D. Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis. *Biochem J* 2005; 387: 703-710 [PMID: 15579135 DOI: 10.1042/BJ20041650]

de Vries B, Snoeijis MG, von Bonsdorff L, Ernest van Heurn LW, Parkkinen J, Buurman WA. Redox-active iron released during machine perfusion predicts viability of ischemically injured deceased donor kidneys. *Am J Transplant* 2006; 6: 2686-2693 [PMID: 16889604 DOI: 10.1111/j.1600-6143.2006.01510.x]

Omar R, Nomikos I, Piccorelli G, Savino J, Agarwal N. Prevention of postschaemic lipid peroxidation and liver cell injury by iron chelation. *Gut* 1989; 30: 510-514 [PMID: 2714683 DOI: 10.1136/gut.30.4.510]

Pippard MJ, Callender ST. The management of iron chelation therapy. *Br J Haematol* 1983; 54: 503-507 [PMID: 6871105 DOI: 10.1111/j.1365-2457.1983.tb02128.x]

Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD. Use of desferrioxamine in the treatment of aceruloplasminemia. *Ann Neurol* 1997; 41: 404-407 [PMID: 9066364 DOI: 10.1002/ana.410410318]

P-Reviewer Lopez-Andujar R  S-Editor L-Editor A  E-Editor Zhang DN